SCION CARDIO-VASCULAR CAPABILITIES BROCHURE

COVER HEADLINE:    Simple Medical Solutions that Save Lives

SUB HEAD:   A Simple Approach to Complex Medical Problems

In today's world of skyrocketing healthcare costs, physicians must continually seek innovative ways to perform complex procedures for less.

Scion Cardio-Vascular (NYSE SCV) is a state-of-the -art company that has risen to this challenge. In just a short time, Scion Cardio-Vascular has built a solid reputation for creating ground-breaking, minimally-invasive medical devices and technology. Our simple solutions are not only creative, cost-effective, versatile, uncomplicated, and quick to market – they enhance the quality of patient care and save lives. Our approach is revolutionary and so are our results. From an innovative pressure-applied dressing that accelerates hemostasis to an easy-to-use debris retrieval device and sophisticated profusion technology, we have a strong track record for success.

SUB HEAD:   The Birth of a Healthcare Pioneer

Scion Cardio-Vascular was born out of a need for simple solutions in the field of medicine. Our primary objective has always been to create pioneering medical solutions that alleviate pain, enhance human welfare, and extend people’s lives. We are a company of forward-thinking visionaries with diverse experience and a deep understanding of the medical device industry. We operate with a no-boundaries style, pushing the envelope in our field and exceeding expectations.

Each member of Scion Cardio-Vascular’s management team has a minimum of 20 years of intensive knowledge in the medical device industry. We have put together some of the brightest in medicine to make tremendous strides in healthcare. The leadership behind Scion encompasses: The Chairman of an international company that operated primary care medical clinics and provided managed care services to more than 30,000 patients throughout the U.S.; Chairman of a publicly traded infusion therapy company with 36 branches covering 37 states, which grew more than $100 million in annual revenue in three short years; owner of a successful medical device stent company; Chief Biomedical Engineer for the Miami Heart Institute; Consultantand Director of Biomedical Engineering for the non-profit Santiago Cancer Foundation, and a physician and an attorney with significant corporate and healthcare transactional and operational matters skills.We are also fortunate to have access to a national advisory board of top physicians.

SUB HEAD:   Just What the Doctor Ordered

Scion CV is changing the face of healthcare for the better:

Innovative

We are a catalyst for new discoveries in the world of interventional cardio-vascular and minimally invasive surgery. We make the impossible possible. We are dedicated to establishing and maintaining an unmatched legacy of breakthroughs in our field.

Cost-Efficient

Scion Cardio-Vascular ’s simple solutions overcome the typical high costs associated with quality medical care. We make it affordable and easy for physicians and healthcare providers to give their patients the best care possible. All of our products have proven to have significant and tangible economic value time and time again.

Simple

Our less invasive medical devices and technologies are alternatives to major surgery and other medical procedures. They simplify medical care for both the healthcare provider and patient.

Speed to Market

Bigger isn’t always better. Scion Cardio-Vascular uses advanced CAD and unique prototyping technology to develop, design, and test products in a rapidly efficient manner. As a result, our products are able to be introduced to the marketplace faster than companies larger in size.

SUB HEAD:   A Portfolio of Proven Breakthrough Products

The Clo-Sur P.A.D.

The Problem:
Closing a puncture site is a time-consuming and uncomfortable process in most catheterization procedures: Patients must wait in a recovery area setting for several hours before hemostasis and ambulation is achieved. Clinicians must spend a lengthy time applying digital pressure to the puncture site. Safety issues for patients must be addressed. Performance of current closure devices is less than ideal. Ease of use – many closure devices can only be used by trained and experienced clinicians. Cost – closure devices now add significantly to a laboratory’s costs.

Scion CV’s Simple Solution:
The Clo-Sur P.A.D.TM (Pressure Applied Dressing) accelerates hemostasis, resulting in better patient outcomes and more cost-effective utilization of catheterization lab personnel. The Clo-Sur P.A.D.TM uses the proven cell binding activity of PolyprolateTM as a hemostatic agent. The porous Clo-Sur P.A.D.TM has been carefully designed to maximize surface area and speed the natural clotting process. As a non-invasive approach, the Clo-Sur P.A.D.TMis easy to apply to the puncture site. This simple application can be completed by a nurse and does not require a physician to be present. It reduces clinician hold time and allows patients to be moved into a recovery area and discharged more rapidly in most cases.

SCI-PRO

The Problem:
Unfortunately, many coronary by-pass patients develop blockages of the saphenous vein grafts (SVG) or have cerebrovascular disease and are not candidates for endarectomy. These patients are often treated with angioplasty and/or stents to remove blockage and increase blood flow. These procedures introduce the risk of neurological events (e.g. stroke) due to the creation of emboli during the procedure.  

Scion CV’s Simple Solution:
The Sci-Pro distal protection device provides distal protection from emboli that are released during angioplasty or stent placement. The purpose is to remove any emboli that are created from progressing to major organs like the heart or brain. Given the less invasive nature of catheterization procedures, the future use of stents in SVG intervention and CAS is more likely. The ability to provide adequate distal protection has been demonstrated successfully and shows clinically significant results.  

M-BOLUS

The Problem:
Fibroids are a benign tumor of the uterus. They are not cancers. However, they do have a rich blood supply and cause bleeding and pain. Fibroids are also known by the names LEIOMYOMA UTERI, LEIOMYOMA, or MYOMA. 50%-80% of women have fibroids, which are the most common indication for hysterectomy (the most frequently performed major surgical procedure in the U.S. ).

Scion CV’s Simple Solution:
M-Bolus LP microspheres for the embolization of hypervascular tumors and arteriovenous malformations have been developed to offer a unique combination of features:

Spherical, Compressible Spheres: M-Bolus LP microspheres are ideally suited to the flow dynamics of the blood stream. In addition, they are hydrophilic and can be temporarily compressed. These qualities combine to facilitate smooth passage through micro-catheters and blood vessels to the target area, helping ensure effective occlusion (blockage).

Precisely Calibrated Sizing: M-Bolus LP microspheres are available in a range of sizes, allowing the interventional radiologist to select spheres to precisely match the diameter of the blood vessel at the desired point of occlusion.
 
Pre-filled Syringes: All M-Bolus LP microspheres are supplied in a closed-system pre-filled syringe to facilitate preparation and efficiency during the procedure
 
Color Coding: The plungers of the pre-filled M-Bolus LP syringes have been color coded to facilitate preparation and minimize the risk of incorrect size selection

SUB HEAD:   A Healthy and Thriving Company

In just three years, Scion Cardio-Vascular has become a highly profitable company, which is unheard of with most start ups, particularly those in the medical field. Our company and its shareholders have enjoyed explosive growth since our founding and we intend to keep growing. Scion CV has developed some of the most advanced and unique cardio-vascular and minimally invasive devices on the market today.

SUB HEAD:   A Bright and Promising Future

The future for a company like Scion is robust and brimming with opportunities. A growing number of surgical procedures are carried out using minimally invasive techniques, creating a multi-billion dollar market opportunity for the specialized devices and instruments used in these procedures. The United States is presently the largest market for minimally invasive devices, but other markets are also growing rapidly. As the population ages, the demand for Scion CV’s simple solutions in the medical field will continue to escalate in a dramatic fashion as well.

Scion CV is focused on developing new products, exploring new markets, and seizing all opportunities that will enhance our contribution to the medical genre. Scion CV is not only well-positioned for dramatic growth and capabilities in the U.S. , but abroad as well. We are committed to our role as an innovator and global leader in the industry.

SUB HEAD:   Opportunities

Scion Cardio-Vascular (NYSE SCV) is a publicly traded company poised for great prosperity. For more information about our financials and investment opportunities, please contact (name), our

Director of Investor Relations, at (305) 555-1212 or name@scion.com.